Stellenbosch University Immunology Research Group

Publications

2017

1. Predicting tuberculosis treatment outcome using metabolomics.

   Luies L, Reenen MV, Ronacher K, Walzl G, Loots DT. Biomark Med. 2017 Dec;11(12):1057-1067. doi: 10.2217/bmm-2017-0133. Epub 2017 Nov 27.

2. Host blood RNA signatures predict the outcome of tuberculosis treatment.

   Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp G, Tabb DL, Alland D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, Walzl G, Zak DE9; Catalysis TB–Biomarker Consortium. Tuberculosis (Edinb). 2017 Dec;107:48-58. doi: 10.1016/j.tube.2017.08.004. Epub 2017 Aug 12.

3. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.

   Nemes E, Hesseling AC, Tameris M, Mauff K, Downing K, Mulenga H, Rose P, van der Zalm M, Mbaba S, Van As D, Hanekom WA, Walzl G, Scriba TJ, McShane H, Hatherill M; MVA029 Study Team. Clin Infect Dis. 2017 Sep 26. doi: 10.1093/cid/cix834.

4. Suitability of saliva for Tuberculosis diagnosis: comparing with serum.

   Namuganga AR, Chegou NN, Mubiri P, Walzl G, Mayanja-Kizza H. BMC Infect Dis. 2017 Aug 31;17(1):600. doi: 10.1186/s12879-017-2687-z.

5. Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

   Nemes E, Rozot V, Geldenhuys H, Bilek N, Mabwe S, Abrahams D, Makhethe L, Erasmus M, Keyser A, Toefy A, Cloete Y, Ratangee F, Blauenfeldt T, Ruhwald M, Walzl G, Smith B, Loxton AG, Hanekom WA, Andrews JR, Lempicki MD, Ellis R, Ginsberg AM, Hatherill M, Scriba TJ; C-040-404 Study Team and the Adolescent Cohort Study Team. Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648. doi: 10.1164/rccm.201704-0817OC.

6. Changes in Host Immune-Endocrine Relationships during Tuberculosis Treatment in Patients with Cured and Failed Treatment Outcomes.

   Kleynhans L, Ruzive S, Ehlers L, Thiart L, Chegou NN, Conradie M, Kriel M, Stanley K, van der Spuy GD, Kidd M, van Helden PD, Walzl G, Ronacher K. Front Immunol. 2017 Jun 15;8:690. doi: 10.3389/fimmu.2017.00690. eCollection 2017.

7. Detection of a combination of serum IgG and IgA antibodies against selected mycobacterial targets provides promising diagnostic signatures for active TB.

   Awoniyi DO, Baumann R, Chegou NN, Kriel B, Jacobs R, Kidd M, Loxton AG, Kaempfer S, Singh M, Walzl G. Oncotarget. 2017 Jun 6;8(23):37525-37537. doi: 10.18632/oncotarget.16401.

8. Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

   Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium. Nat Med. 2017 Apr 7;23(4):526. doi: 10.1038/nm0417-526a.

9. B-cells with a FasL expressing regulatory phenotype are induced following successful anti-tuberculosis treatment.

   van Rensburg IC, Kleynhans L, Keyser A, Walzl G, Loxton AG. Immun Inflamm Dis. 2016 Dec 27;5(1):57-67. doi: 10.1002/iid3.140. eCollection 2017 Mar.

10. Re: "It May Be Too Early to Try to Prove the Effect of Deworming on Tuberculin Reactivity".

    Van der Zalm MM, van Soelen N, Mandalakas AM, Jacobsen M, Detjen AK, Marx FM, Grewal HM, Cotton MF, WalzlG, Hesseling AC. Pediatr Infect Dis J. 2017 Feb;36(2):241-242. doi: 10.1097/INF.0000000000001408.

11. Cardiovascular risk and endothelial function in people living with HIV/AIDS: design of the multi-site, longitudinal EndoAfrica study in the Western Cape Province of South Africa.

    Strijdom H, De Boever P, Walzl G, Essop MF, Nawrot TS, Webster I, Westcott C, Mashele N, Everson F, Malherbe ST, Stanley K, Kessler HH, Stelzl E, Goswami N. BMC Infect Dis. 2017 Jan 7;17(1):41. doi: 10.1186/s12879-016-2158-y.

12. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa.

    Loxton AG, Knaul JK, Grode L, Gutschmidt A, Meller C, Eisele B, Johnstone H, van der Spuy G, Maertzdorf J, Kaufmann SH, Hesseling AC, Walzl G, Cotton MF; VPM Study Group. Clin Vaccine Immunol. 2017 Feb 6;24(2). pii: e00439-16. doi: 10.1128/CVI.00439-16.

13. High-throughput Identification of DNA-Encoded IgG Ligands that Distinguish Active and Latent Mycobacterium tuberculosis Infections.

    Mendes KR, Malone ML, Ndungu JM, Suponitsky-Kroyter I, Cavett VJ, McEnaney PJ, MacConnell AB, Doran TM, Ronacher K, Stanley K, Utset O, Walzl G, Paegel BM, Kodadek T. ACS Chem Biol. 2017 Jan 20;12(1):234-243. doi: 10.1021/acschembio.6b00855. Epub 2016 Dec 13.